Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Phoenix, Arizona 85013


Purpose:

The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.


Study summary:

SGS742 is a GABA(B) receptor antagonist. It is an orally active drug and possesses neurochemical and psychopharmacologic features that suggest it could improve memory and cognition in humans. The primary objective of the SGS742 clinical trial will be to determine the effect of SGS742 on memory and cognition in individuals diagnosed with mild to moderate Alzheimer's disease. The duration of the study is 3 months with 5 clinic visits.


Criteria:

Inclusion Criteria: - 55 to 90 years of age - Diagnosed with mild to moderate Alzheimer's disease - Willing caregiver - In general good health Exclusion Criteria: - Call 1-877-MY-MEMORY and ask to be referred to a study center located near you for entry criteria information. Prohibited Meds: - Alzheimer's medications (Aricept, Exelon, Remydl, Nemenda)


NCT ID:

NCT00093951


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Phoenix, Arizona 85013
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.